Lindsey Rolfe
Director/Board Member en ATRECA, INC. .
Fortuna: - $ al 31/03/2024
Perfil
Lindsey Rolfe is an Independent Director at Atreca, Inc. and CERo Therapeutics Holdings, Inc. They are also a Member at The Royal College of Physicians.
Previously, Dr. Rolfe worked as the Chief Medical Officer & Executive VP-Clinical at Clovis Oncology, Inc. Dr. Rolfe holds a doctorate degree from The University of Edinburgh.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
ATRECA, INC. CLASS A
-.--% | 13/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
-.--% | 05/04/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Lindsey Rolfe
Empresas | Cargo | Inicio |
---|---|---|
ATRECA, INC. | Director/Board Member | 22/08/2019 |
The Royal College of Physicians | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Lindsey Rolfe.
Empresas | Cargo | Fin |
---|---|---|
CLOVIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 01/06/2023 |
Formación de Lindsey Rolfe.
The University of Edinburgh | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ATRECA, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Bolsa de valores
- Insiders
- Lindsey Rolfe